Expertise in
3
conditions

Dr. Dustin R. Fraidenburg

Pulmonary Medicine | Intensive Care Medicine
The Board Of Trustees Of The University Of Illinois
840 S Wood St Mc, 787 Uic Medicine, 
Chicago, IL 
 (849.9 mi)
Accepting New Patients
Offers Telehealth
16 Years of Experience
Expertise in
3
conditions
The Board Of Trustees Of The University Of Illinois
840 S Wood St Mc, 787 Uic Medicine, 
Chicago, IL 
 (849.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Dustin Fraidenburg is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Chicago, Illinois. Dr. Fraidenburg has been practicing medicine for over 16 years is highly rated in 3 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Cerebral Hypoxia, Pulmonary Veno-Occlusive Disease, and Systemic Sclerosis (SSc). Dr. Fraidenburg is currently accepting new patients.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Wayne State University School Of Medicine, 2009
Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in IL
Hospital Affiliations
University Of Illinois Hospital And Clinics
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna

Locations

THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
840 S Wood St Mc, 787 Uic Medicine, Chicago, IL 60612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

30 Total Publications

Not to Be Forgotten, Pulmonary Vascular Effects of Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease.
Not to Be Forgotten, Pulmonary Vascular Effects of Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease.
Journal: Annals of the American Thoracic Society
Published: January 21, 2025
Similar Doctors
Expertise in
30
conditions
Dr. Mary E. Strek
Pulmonary Medicine | Intensive Care Medicine
Expertise in
30
conditions
Dr. Mary E. Strek
Pulmonary Medicine | Intensive Care Medicine

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (7.7 mi)
773-702-1000
Languages Spoken:
English, French, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mary Strek is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Chicago, Illinois. Dr. Strek is highly rated in 30 conditions, according to our data. Her top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Lung Transplant. Dr. Strek is currently accepting new patients.

Expertise in
18
conditions
Dr. Daniel F. Dilling
Intensive Care Medicine | Pulmonary Medicine
Expertise in
18
conditions
Dr. Daniel F. Dilling
Intensive Care Medicine | Pulmonary Medicine

Loyola University Medical Center

2160 S 1st Ave, Suite 150, 
Maywood, IL 
 (7.7 mi)
708-216-9000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Daniel Dilling is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Maywood, Illinois. Dr. Dilling is highly rated in 18 conditions, according to our data. His top areas of expertise are Lymphangioleiomyomatosis, Pulmonary Fibrosis, Acute Interstitial Pneumonia, Lung Transplant, and Gastrostomy. Dr. Dilling is currently accepting new patients.

Momen M. Wahidi
Expertise in
14
conditions
Dr. Momen M. Wahidi
Pulmonary Medicine | Intensive Care Medicine
Expertise in
14
conditions
Dr. Momen M. Wahidi
Pulmonary Medicine | Intensive Care Medicine

Northwestern Medical Faculty Foundation

675 N St Clair, 250 Dept Of Pulmonary, 
Chicago, IL 
 (4.0 mi)
312-695-1800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Momen Wahidi is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Chicago, Illinois. Dr. Wahidi is highly rated in 14 conditions, according to our data. His top areas of expertise are Pleural Effusion, Lymphofollicular Hyperplasia, Lung Nodules, Endoscopy, and Advanced Bronchoscopy. Dr. Wahidi is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile